Form D · Other Health Care
Cage Pharmaceuticals, Inc.
New York, NY · CIK 0001727073
Offering snapshot reported May 31, 2024 · SEC filing
- Reported sold
- $137K Offering amount: $137K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 31, 2024 | Initial | $137,490 | No comparison | 2 | SEC filing |
| Jul 12, 2019 | Initial | $480,000 | No comparison | 1 | SEC filing |
| Jan 5, 2018 | Initial | $350,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-514783
Source: Form D, filed May 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Malik | Director |
| Peter Olagunju | Director, Executive |
| Nick Papadopoulos | Director |
| Jason Rifkin | Executive |
| Isaac Ro | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
512 W. 22nd Street 5th Floor
New York, NY, 10011
New York, NY, 10011